Skip to Content

News

Roche Wins Approval for Targeted Cancer Drug Vismodegib

Date Posted: January 31, 2012

Date Posted: January 31st, 2012 Summary: Yesterday the FDA announced that Roche and Genentech had been granted approval for the targeted cancer drug, Vismodegib for the treatment of basal cell carcinoma. The approval was granted under the agency’s priority review program that provides for an expedited six-month review of drugs that may offer major advancesContinue Reading

Read more >>

Accelerator MS: It’s Role as a Frontline Bioanalytical Technique

Date Posted: December 23, 2011

Summary: A paper on a presentation by Dr Mark Seymour on the use of AMS as a frontline technique in bioanalytical detection has been published in the December 2011 issue of Bioanalysis. The paper was presented at the Reid Bioanalytical Forum in July earleir this year. The full paper can be downloaded from the FutureContinue Reading

Read more >>

Xceleron Publish Data on Quantitative Target Binding in vivo

Date Posted: November 28, 2011

Summary: Target Mediated Disposition of 14C-anti-CEA using Accelerator Mass Spectrometry It has been shown in a previous study using Iodine-125, that the plasma clearance of T84.66 (anticarcinoembryonic antigen, CEA) in a xenograft mouse model can be used to test for the presence of CEA-positive tumors. Transferring the technique into humans would be problematic because ofContinue Reading

Read more >>

AAPS Poster with AstraZeneca Comparing IV Tracer Design with Oral/IV Crossover Clinical Design

Date Posted: November 24, 2011

Summary: A Resource and Data Quality Comparison: Absolute Bioavailability Data from an Oral / IV Crossover and an IV Isotropic Tracer Clinical Design. This poster, presented by AstraZeneca and Xceleron at the meeting of the American Association of Pharmaceutical Scientists (AAPS) in Washington DC in October 2011, describes the us of an IV microtracer studyContinue Reading

Read more >>

AAPS Poster with Unilever and the University of Vienna on Measurement of Metabolic Turnover.

Date Posted: November 9, 2011

Summary: Probing Intrinsic Pathways: a Novel Approach to the Measurement of Metabolic Turnover. Studying compounds with high natural occurrence or dietary background in humans is problematic because the dose of metabolite or precursor must be very small to avoid perturbing naturally-occurring pools, intravenous administration is required to obtain clearance and metabolic-turn-over data, and extreme sensitivityContinue Reading

Read more >>